Effects of Semaglutide combined with Metformin in treatment of obese patients with type 2 diabetes mellitus
Objective:To observe effects of Semaglutide combined with Metformin in treatment of obese patients with type 2 diabetes mellitus(T2DM).Methods:A prospective study was conducted on the clinical data of 132 obese T2DM patients admitted to the hospital from March 2021 to February 2023.They were divided into control group and observation group according to the random number table method,66 cases in each.The control group was treated with Repaglinide combined with Metformin,while the observation group was treated with Semaglutide combined with Metformin.The clinical efficacy,the levels of glucose and lipid metabolism indexes[fasting plasma glucose(FPG),fasting insulin(FINS),total cholesterol(TC),insulin resistance index(HOMA-IR)],the levels of inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 92.42%(61/66),which was higher than 80.30%(53/66)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FPG,TC and HOMA-IR in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of CRP and IL-6 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the observation group was 6.00%(7/66),which was lower than 24.24%(16/66)in the control group,and the difference was statistically significant(P<0.05).Conclusions:Semaglutide combined with Metformin in the treatment of the obese patients with T2DM can improve the clinical efficacy,regulate the levels of glucose and lipid metabolism,reduce the body's micro-inflammatory response,and reduce the incidence of adverse reactions.Moreover,it is superior to Metformin combined with Repaglinide treatment.
SemaglutideMetforminRepaglinideObeseType 2 diabetes mellitusGlucose and lipid metabolismMicroinflammatory state
NETL
NSTL
万方数据
